Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

被引：0

作者：

Kavan, P. ^{[1
]}

Rho, H. ^{[1
]}

Probst, S. ^{[2
]}

Abikhzer, G. ^{[2
]}

Rho, Y. S. ^{[3
]}

Barrera, I ^{[1
]}

机构：

[1] McGill Univ, Segal Canc Ctr, Dept Med Oncol, Montreal, PQ, Canada

[2] Jewish Gen Hosp, Div Nucl Med, Montreal, PQ, Canada

[3] Univ Hawaii, John A Burns Sch Med, Honolulu, HI USA

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷

关键词：

neuroendocrine tumor; lutetium; prrt; efficacy; safety;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H21

引用

页码：193 / 193

页数：1

共 43 条

[41] Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours [J].

Davidson, Jennifer ;

Hull, Avril ;

Mead, Trish ;

Lunt, Brian ;

Stewart, Allan .

JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2022, 53 (02) :S22-S30

[42] Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 [J].

Nicolas, G. ;

Baum, R. ;

Herrmann, K. ;

Lassmann, M. ;

Hicks, R. ;

Haug, A. R. ;

Oberwittler, H. ;

Bouterfa, H. ;

Wang, T. ;

Wild, D. .

NEUROENDOCRINOLOGY, 2017, 105 :250-250

[43] Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors [J].

Parghane, Rahul ;

Talole, Sanjay ;

Basu, Sandip .

WORLD JOURNAL OF NUCLEAR MEDICINE, 2019, 18 (02) :160-170

← 1 2 3 4 5 →